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Transcriptional control: Versatile molecular glue
Ralf Janknecht and Tony Hunter
CBP and p300 are versatile coactivators that physically
connect many DNA-binding factors to the basal
transcription machinery. Phosphorylation by cyclin-
dependent or signal-induced protein kinases may
regulate their function.
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Initiation of transcription by RNA polymerase II
commonly requires the cooperation of two different sets of
proteins, the basal transcription machinery and sequence-
specific factors that bind to promoter/enhancer elements.
How do the latter transcription factors relay their activat-
ing or repressing function to the basal transcription
machinery? One way would be by direct interaction of the
sequence-specific transcription factors with components
of the basal transcription machinery, such as the TATA-
box binding protein (TBP) or its associated factors
(TAFs). Alternatively, bridging proteins may establish an
indirect contact. During the last three years, a family of
mammalian bridging proteins has been identified, consist-
ing of CREB-binding protein (CBP) and p300. These very
similar proteins are coactivators of transcription that them-
selves do not specifically interact with promoter elements
but rather are recruited to promoters by protein–protein
interactions [1,2]. CBP and p300 act as a crucial scaffold
for the formation of transcriptional initiation complexes
and their activity might be regulated by phosphorylation.
Coactivation of cAMP-stimulated transcription
CBP was originally identified by its ability to interact with
the cAMP-response element binding protein (CREB).
CREB itself requires phosphorylation by cAMP-depen-
dent protein kinase (PKA) at serine 133 to be activated.
The mechanism by which this enhances the transactiva-
tion function of CREB has now been resolved: this phos-
phorylation is necessary for interaction with the
coactivator CBP, or alternatively p300 [1,2]. CBP interacts
directly with phosphoserine 133 through residues
590–669 [3], making it one of the first proven phosphoser-
ine-recognizing proteins.
In addition to binding to phospho-CREB, CBP can bind to
the basal transcription factor TFIIB (Fig. 1) and thereby
act as a bridging molecule between phospho-CREB and
the basal transcription machinery [1]. Functionally, CBP
and p300 enhance CREB-mediated transcription upon
PKA activation [1,2,4]. This coactivation can be sup-
pressed by expressing the adenoviral protein E1A, which
sequesters CBP and p300 by directly binding to them [2].
As CREB’s E1A-binding domain overlaps its TFIIB-
binding domain (Fig. 1), binding of E1A could preclude
interaction of TFIIB with CBP or p300 and thereby
inhibit CREB function.
Phosphorylation of CREB solely at serine 133 is also
elicited upon T-cell receptor activation independently of
PKA, and protein kinase C appears to be responsible [5].
Unexpectedly, this does not lead to transcriptional
coactivation by CREB and CBP. Costimulation with a
cAMP agonist at a suboptimal dose, however, which does
not induce CREB phosphorylation, is able to achieve this.
These data imply that phosphorylation by PKA of a factor
other than CREB, which might be CBP itself (see below),
is required for CREB and CBP to coactivate transcription.
CREB and CBP may also form a complex independently
of PKA activation at the human T-cell leukaemia virus-1
(HTLV-1) long terminal repeat [6]. This interaction is
mediated by the viral Tax protein, which appears to be an
adaptor between CREB and CBP. Surprisingly, formation
of a tripartite CREB–CBP–Tax complex depends on PKA
phosphorylation of CREB when CREB is bound to the
somatostatin cAMP-response element. This suggests that
the nature of the recognition sequence bound by CREB
may dictate different modes of protein–protein interaction
within the tripartite complexes.
Figure 1
Mouse CBP. Regions 1–101, 461–661, 1621–1891 and 2058–2163
contain binding sites for the proteins indicated below. The
bromodomain comprises residues 1107–1171; the two zinc fingers
comprise residues 1284–1312 and 1708–1733. The domain
structure of p300 appears to be basically similar.
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CBP and p300: promiscuous molecules
Injection of anti-CBP antibodies into cells inhibits not
only cAMP-stimulated gene activation but also E1A-sensi-
tive gene activation by mitogens or hormones  ([4,7] and
D. Chakravarti and R. Evans, personal communication),
indicating that CBP has various interaction partners.
Indeed, CREB [3], c-Jun [4,8], c-Myb and v-Myb [9,10],
and Sap-1a and Elk-1 ([11] and R.J. and A. Nordheim,
unpublished data) all interact with CBP residues 461–661.
In addition, c-Fos [12] and the nuclear receptors for
steroids, thyroids and retinoids [7] interact with CBP
residues 1621–1877 or 1–101, respectively. Unlike CREB,
however, most or all of these proteins do not require phos-
phorylation to bind to CBP (the situation with c-Jun
remains controversial).
Like CREB, the nuclear hormone receptors require
activation — in their case by binding cognate hormone —
to interact with CBP [7]. Thus, the observed inhibition of
the transcription factor AP-1 — composed of c-Jun, c-Fos
and related factors — by nuclear receptors upon hormone
binding can be explained by the competition for a limiting
cofactor, namely CBP. Furthermore, the nuclear hormone
receptor coactivator p160SRC-1 can interact with residues
2058–2163 of CBP, and may stabilize the interaction
between nuclear hormone receptors and CBP ([7] and D.
Livingston, personal communication).
Interestingly, c-Fos binds to the same CBP region as E1A
[12]. E1A-mediated inhibition of c-Fos activity could
therefore be due to competition between E1A and c-Fos
for the same binding site in CBP. This also suggests that,
like E1A, binding of c-Fos precludes TFIIB binding to
CBP. If so, CBP must be capable of contacting another
component of the basal transcription machinery to coacti-
vate c-Fos-mediated transcription. This may be TBP, as
TBP binds to both the amino- and carboxy-terminal
regions of p300 in vitro, implying that p300 can act as a
TAF [13]. Like c-Fos and CBP, the basic helix–loop–helix
protein MyoD appears to interact with p300 through the
region that is also bound by E1A, and this interaction is
critical for muscle differentiation ([13] and D. Livingston,
personal communication).
Surprisingly, E1A acts positively in combination with the
transcription factor YY1 [14]. No direct interaction between
E1A and YY1 was reported, but rather p300 can bind to both
proteins at the same time, resulting in a tripartite complex.
The YY1-binding domain was coarsely mapped to the last
800 residues of p300, but apparently it does not overlap with
the E1A-binding domain [14]. That the YY1–p300–E1A
complex, but not the CREB–p300–E1A complex, can facili-
tate transcriptional activation may be because the two
tripartite complexes have different geometries.
Phosphorylation of p300 and CBP
Although p300 is phosphorylated in both quiescent and
proliferating cells, the phosphorylation levels change
during the cell cycle and hyperphosphorylation occurs
during mitosis [15]. This suggests that p300 could be a
substrate for cyclin-dependent protein kinases (Cdks).
Consistent with this, Cdk2 and Cdc2 are capable of phos-
phorylating p300 in vitro [16]. E1A expression in adeno-
virus-infected cells might promote phosphorylation of
p300, as E1A can bind simultaneously to p300 and either
pRB, p107 or p130, all of which can recruit cyclin–Cdk2
via cyclin interactions into a multiprotein complex [17,18].
Cdc2-related protein kinases are activated during retinoic
acid-triggered differentiation of F9 cells. Like retinoic
acid, adenoviral infection elicits differentiation of F9 cells
and both stimuli result in hyperphosphorylation of p300
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Figure 2
Models for the phosphorylation-dependent
cooperation between CBP and Sap-1a (a),
CREB (b) or NF-M (c). Note that it is unclear
whether two molecules of CBP can be
recruited by a single CREB or NF-M dimer.
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[19]. In mouse primary keratinocytes or myoblasts, trans-
cription of the p21 gene, which encodes a Cdk-inhibitor, is
stimulated upon Ca2+-induced differentiation. Normal
E1A, but not mutant forms incapable of binding to p300,
suppresses p21 activation, suggesting that p300 is
involved. After p21 activation, which leads to reduced
Cdk2 activity, the phosphorylation level of p300 appears
to decrease [20], supporting the notion that p300 phospho-
rylation is in part due to Cdks. Thus, differentiation of
cells can be associated with both hyperphosphorylation or
hypophosphorylation of p300. The extent and sites of
p300 phosphorylation may determine which interaction
partners bind to p300, as SV40 large T antigen coimmuno-
precipitates only with hypophosphorylated p300 [21], an
interaction which, like that with E1A, suppresses p300-
dependent transcription ([21] and R. Eckner, personal
communication).
CBP is phosphorylated in vivo within its carboxy-terminal
glutamine-rich region. In vitro, CBP can be phosphory-
lated within this region by ERK-subclass mitogen-acti-
vated protein kinases (MAPKs) or PKA, both of which can
enhance CBP’s transactivation potential ([11] and R.J. and
A. Nordheim, unpublished data). This raises the possibil-
ity that CBP is a target of signal transduction pathways
funnelling through ERK-MAPK or PKA. ERK-MAPK and
PKA together do not have a cooperative effect on CBP,
rather PKA reduces the activation by ERK-MAPK [11].
Conversely, Ras activation, which leads to ERK-MAPK-
mediated phosphorylation, activation and nuclear translo-
cation of the pp90rsk protein kinase, induces association of
pp90rsk with CBP and thereby inhibits cAMP-mediated
gene transcription in a manner similar to E1A (M. Mont-
miny, personal communication). Thus, CBP may be a
dampening integrator of ERK-MAPK and PKA signalling
pathways.
Sap-1a and Elk-1, which are recruited by the serum
response factor (SRF) to the serum response element
(SRE) of c-fos, activate transcription upon MAPK stimula-
tion. Sap-1a and Elk-1 interact with CBP in a phosphory-
lation-independent manner, yet this does not lead to an
enhancement of transcription. Rather, Sap-1a and Elk-1
have to be phosphorylated by MAPK in order to stimulate
the c-fos SRE together with CBP ([11] and R.J. and A.
Nordheim, unpublished data). As ERK-MAPK also phos-
phorylates and thereby stimulates CBP — perhaps by
inducing a conformational change that unmasks CBP’s
activation domains — ERK-MAPK plays a dual role in the
activation of the SRE (Fig. 2a).
The cAMP–PKA pathway of gene activation may similarly
involve phosphorylation of both CREB, allowing it to
recruit CBP, and of CBP, increasing its coactivation poten-
tial (Fig. 2b). Phosphorylation of CREB at serine 142 by
Ca2+/calmodulin-dependent protein kinase II blocks the
activation of CREB by cAMP. This phosphorylation does
not interfere with the ability of CREB — also phosphory-
lated at serine 133 — to interact with CBP, demonstrating
that interaction of CREB and CBP is not sufficient for
coactivation. Functional cooperation may require an
induced conformational change in CBP that is precluded
by phosphorylation of CREB at serine 142 [22]. 
Coactivation by the CAAT/enhancer-binding protein
NF-M and CBP is detectable in the presence of oncogenic
Ras [10]. Oncogenic Ras triggers activation of ERK-
MAPK, which phosphorylates both NF-M and CBP; the
latter phosphorylation increases CBP’s coactivation poten-
tial, and the former may induce a conformational changes
that leads to an interaction between NF-M and CBP (Fig.
2c). Other hypotheses cannot be ruled out — the phos-
phorylation of CBP may be required for the NF-M–CBP
interaction, or NF-M and CBP may cooperate less directly
(the two proteins have not yet been shown to interact
physically).
Concluding remarks
How many more CBP/p300 interaction partners — either
sequence-specific transcription factors, coactivators or
components of the basal transcription machinery — will
be discovered in the near future? There are probably a
plethora of them. And mammals may have more members
of the CBP/p300 family. Will all members of this family
turn out to act similarly? Although CBP and p300 can
substitute for each other in their interactions with CREB,
nuclear hormone receptors and c-Myb [2,7,10], the DRF1
and DRF2 transcription factor complexes that regulate
c-jun induction by retinoic acid appear to contain p300 but
not CBP [19]. Whether CBP or p300 is present, the
precise three-dimensional geometry of the multiple
CBP/p300 contacts with such complexes is presumably
critical for efficient stimulation (or inhibition) or transcrip-
tional initiation.
What phenotype would CBP or p300 knockout mice be
expected to have? If CBP and p300 can widely substitute
for each other, little effect may be noticeable. If CBP and
p300 perform different functions, however, given their
promiscuity one might expect the knockout mice to have
pleiotropic defects, some of which may be exhibited even
in a hemizygous animal. In this regard, the autosomal
dominant Rubinstein-Taybi syndrome is associated with
the mutation of one CBP allele [23], but it is still possible
that another, unknown gene causes this disease. Analysis
of a small number of colorectal and gastric carcinomas
revealed that two of them displayed the loss of one p300
allele and a somatic point mutation in the other one [24].
This, together with the ability of p300 to suppress cell
transformation by E1A [25], points to the possibility that
p300 is a tumor suppressor, as had originally been sus-
pected from its discovery as an E1A-associated protein.
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